Company Overview
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Recent Developments
- Dec 2025 Revenue of $6.94M (-23.2% YoY); net profit $-212.39M.
- Trailing 12 Months Year-on-year growth — revenue -23.2%.
- 5-Year Trend Long-term compounding — profit CAGR -158.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -23.23% |
Compounded Profit Growth
| 5 Years: | -158.55% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +165.45% |
| 6 Months: | +7.21% |
| 3 Months: | -0.13% |
| 1 Month: | +23.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.33 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -158.6% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMNM Immunome, Inc. R2K | 22.59 | -9.45 | $2.56B | 0.00% | -35.12% | -50.14% | - | -158.55% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 2.36M | 4.26M | 3.56M | 1.03M | 2.36M | - | - | 2.93M | 4.01M | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.56M | 50.49M | 60.14M | 72.86M | 59.33M |
| Operating Income | -2.72M | -2.65M | -2.71M | -2.82M | -3.90M | -5.74M | -7.72M | -11.65M | -8.93M | -8.53M | -4.47M | -5.77M | -4.63M | -132.30M | -40.01M | - | - | -44.64M | -46.48M | -60.14M | -72.86M | -59.33M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -43.91M | -45.76M | -59.41M | -72.08M | -58.58M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -41.64M | -43.40M | -57.46M | -69.90M | -53.84M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.74M | -2.68M | -2.71M | -8.38M | -3.90M | -5.24M | -7.72M | -11.65M | -8.92M | -8.53M | -4.27M | -5.56M | -4.34M | -129.49M | -36.12M | - | - | -41.64M | -43.40M | -57.46M | -69.90M | -53.84M |
| Diluted EPS | - | - | - | - | -0.37 | -0.46 | -0.65 | -0.96 | -0.74 | -0.75 | -0.35 | -0.46 | -0.36 | -2.51 | -0.60 | -0.78 | - | -0.52 | -0.50 | -0.65 | - | -0.48 |
| R&D Expense | 2.23M | 2.12M | 1.89M | 1.64M | 1.98M | 3.23M | 4.51M | 8.08M | 5.72M | 5.22M | 3.91M | 5.72M | 3.82M | 15.37M | 29.08M | 37.20M | - | 36.87M | 40.45M | 49.19M | - | 46.38M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 36.90M | 42.75M | 162.50M | 231.05M |
| Operating Income | -10.35M | -12.26M | - | -36.90M | -28.73M | -153.46M | -224.11M |
| EBITDA | - | - | - | -36.27M | -28.00M | -151.35M | -221.16M |
| Interest Expense | - | - | 10.00K | - | - | - | - |
| Pretax Income | - | - | - | -36.90M | -106.81M | -292.96M | -212.39M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -10.44M | -17.84M | - | -36.90M | -106.81M | -292.96M | -212.39M |
| Diluted EPS | - | -5.26 | - | -3.09 | -5.38 | -5.00 | -2.43 |
| R&D Expense | 8.82M | 7.49M | 14.11M | 23.27M | 23.09M | 129.54M | 177.29M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 5.06M | 44.52M | - | 24.05M | 148.54M | 240.24M | 683.19M |
| Current Assets | - | - | - | - | 22.65M | 144.70M | 221.34M | 660.78M |
| Cash & Equivalents | - | 2.54M | 39.77M | - | 20.32M | 98.68M | 143.35M | 653.48M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | 0 | 847.00K | - | - | - |
| Total Liabilities | - | 1.80M | 3.18M | - | 7.39M | 28.66M | 59.08M | 48.84M |
| Current Liabilities | - | 1.67M | 3.04M | - | 7.33M | 21.83M | 54.31M | 44.99M |
| Long Term Debt | - | - | 134.00K | - | - | - | - | - |
| Total Debt | - | - | - | - | 291.00K | 1.65M | 4.83M | 3.85M |
| Total Equity | -25.20M | -35.63M | 41.34M | - | 16.65M | 119.88M | 181.16M | 634.34M |
| Shares Outstanding | - | - | - | - | 12.13M | 43.25M | 64.46M | 113.13M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.60M | -12.13M | -18.23M | -28.69M | -7.57M | -110.79M | -190.92M |
| Investing Cash Flow | -233.00K | -586.00K | -79.00K | -248.00K | -30.48M | -85.06M | 60.80M |
| Financing Cash Flow | 10.77M | 49.94M | 27.77M | 32.00K | 116.41M | 240.53M | 640.36M |
| Capital Expenditure | -233.00K | -586.00K | -79.00K | -248.00K | -831.00K | -7.17M | -9.69M |
| Free Cash Flow | -9.83M | -12.72M | -18.30M | -28.94M | -8.40M | -117.97M | -200.60M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -204.9% | -1,697.3% | -3,228.8% |
| Net Margin % | - | - | - | - | -761.9% | -3,240.4% | -3,060.0% |
| ROE % | 29.3% | -43.1% | - | -221.6% | -89.1% | -161.7% | -33.5% |
| ROCE % | -304.8% | -29.6% | - | -220.8% | -22.7% | -82.5% | -35.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.98% | 16.97M | $405.07M |
| 2 | T. Rowe Price Investment Management, Inc. | 14.45% | 16.36M | $390.61M |
| 3 | Blackrock Inc. | 7.21% | 8.17M | $194.99M |
| 4 | Redmile Group, LLC | 4.91% | 5.56M | $132.69M |
| 5 | State Street Corporation | 4.77% | 5.40M | $128.90M |
| 6 | Primecap Management Company | 4.23% | 4.79M | $114.30M |
| 7 | Wellington Management Group, LLP | 4.18% | 4.73M | $112.95M |
| 8 | Vanguard Capital Management LLC | 3.91% | 4.43M | $105.74M |
| 9 | Driehaus Capital Management, LLC | 3.62% | 4.10M | $97.86M |
| 10 | Enavate Sciences Gp, LLC | 3.19% | 3.61M | $86.26M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMNM
Immunome Stock Up 32% in a Month: Here's What You Should Know - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQVENlSUc5bl9TWlJKR1g4ZlBfT3FsbXJkb09GLW9zcWZaTXBCV2pkeUNMcUw4RjYtcXBOdk1jOV9LYWFHWE1fSk96T1Z4eGllR3Fsdl83Zkc4Z1FCUzJza3owajRITkFpQVNHZXpGbHBzVlVXNm1Vc2RoQnVRdGI3TlNCc1hGS1gzdDhWbj…
Insider Sale: CHIEF BUSINESS OFFICER of $IMNM Sells 1,092 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOcXlnWXM4dXdpaXFHbkdXbWZTSmttNGU1QzZsU1BQV3lUSmdCN29CVm1idnY0NHBmNUI2aDExb2RCZUR5enA4N2hUMlRad1ZETEN0dUIwNzBjSlFjOThHVFd0RXY4QUl1cU9ZakNLaXJEYU9KWGh1c1BWRjAtMHpocUhqNHFUR21uMS1TUH…
Why Immunome (IMNM) Is Up 11.7% After FDA Accepts Varegacestat NDA For Desmoid Tumors - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPZ3ZJOVE5MDVrbVJMWTdZTXBmSmNjYmJWZm12R3UtaTVSVk5hbnV3dFpPd0FrMFBqLVgzUEhVWUs5QUM3TE5CaGNqd0g5cHV1cnZ1ZXd4VzVXTGp0cEprOU9TZi14WlNCUzJCeENfc2ZFdlBzRlZPLUV2WlVvQ1E0RWcxYXRoMWc1WktBST…
Immunome’s desmoid tumor drug wins FDA review, April 2027 date set - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQYklOcVhlUjU0cjFrc0tmUEVmTXB3SXNORVVsVGZnVXVDUWVmZ0RjN2FoZnpVOENiRzVOUDdwSmNBMUZ3TkRQeDNXa3VUZkNySm1PczZRNzhlaGJuUy1QQUx2cnRxMlVTUDZ3QUw1bUFxYkhPOVlkWEdtQmVNMnJjbGdPa2hKajc1VUFLc2…
TD Cowen reiterates Buy on argenx stock, cites IMNM opportunity - Investing.com
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNRW05WTFOM2tIOGV6UjdkbkRDTWdWQ2pyRlFNSXN1M1J1eDhMVHNLWU9feTJ2TnVPcFVvSmt4aWpHd0p2azF2My16aVdJWWZ3S0VTZHc2TU44THJrME5CZDkzVzJMV3h2ZmFHUnJsaUtSQW8tTHhlYmxNSFhEN2puUFVrX2piUlpGZFZ0OU…
Immunome(IMNM.US) Director Sells US$4.39 Million in Common Stock - Moomoo
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQQ1EzMWo3NWU5dnF2QzJkM0VVUXl0NklhQV9QWFkxS2twM2pDX285M3NJVEtmS0ZoRThGSU91RkNRaURpYkhLdWVjckJIZWR4Uy1NQ2RkSXhBOHJtbTB2VTg0anRuZUJnWjdEZkhSTXNWZ2l0Qm0wYXhRSTBQU2JUV3N4cmZ4dU1lbW1zcV…
IMNM — Frequently Asked Questions
What is the current share price of Immunome, Inc. (IMNM)?
As of 2026-07-14 21:23 PDT, Immunome, Inc. (IMNM) trades at $22.59 on NasdaqCM. Its 52-week range is $8.40 to $26.97.
What is the market capitalisation of IMNM?
Immunome, Inc. (IMNM) has a market capitalisation of $2.56B on NasdaqCM.
What is the P/E ratio of IMNM?
IMNM trades at a trailing price-to-earnings (P/E) ratio of -9.45. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.53.
What is the return on equity (ROE) of IMNM?
IMNM has a return on equity (ROE) of -50.14%. Its return on capital employed (ROCE) is -35.12%.
Is IMNM a good stock to buy?
This page provides a data-driven analysis of Immunome, Inc. (IMNM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.